Related Experiment Video

Updated: Aug 11, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute

Alexander Claviez, Cornelia Eckert, Karl Seeger

    Haematologica
    |February 8, 2006
    PubMed

    Insights

    Rituximab combined with chemotherapy offers a potential treatment for relapsed B-cell precursor acute lymphoblastic leukemia (B-ALL). Two of three children achieved long-term remission after subsequent stem cell transplant.

    Area of Science:

    • Pediatric Oncology
    • Hematology
    • Immunotherapy

    Background:

    • Relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) presents a significant therapeutic challenge in pediatric patients.
    • Standard chemotherapy regimens often show limited efficacy in this aggressive subtype of leukemia.

    Observation:

    • This study investigated the efficacy of rituximab in combination with chemotherapy for three children diagnosed with relapsed/refractory B-ALL.
    • The treatment aimed to reduce the minimal residual disease (MRD) load, a key indicator of treatment response.

    Findings:

    • The combination therapy resulted in a decreasing or persistently low positive MRD load in all three treated children.
    • Two of the three patients proceeded to allogeneic stem cell transplantation (SCT) and achieved durable complete remission.

    Implications:

    • Rituximab plus chemotherapy may serve as a bridge to potentially curative allogeneic SCT for pediatric B-ALL.
    • Further research is warranted to optimize this combination therapy and evaluate its long-term outcomes in a larger cohort.

    More Related Videos

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.